Bordet R, Thomas P, Dupuis B
Réseau de Recherche et d'Expérimentation Psychopharmacologique (REPP), Centre Hospitalier et Universitaire, Lille, France.
Am J Psychiatry. 1998 Oct;155(10):1346-51. doi: 10.1176/ajp.155.10.1346.
The purpose of this study was to investigate the effect of pindolol to accelerate the onset of action of paroxetine in patients suffering from major depression.
Patients who met DSM-IV criteria for a nonpsychotic disorder, who had no previously treated episode of major depression episode, and who had a score of at least 18 on the 17-item Hamilton Depression Rating Scale were randomly assigned, for the first 21 days, to treatment with paroxetine (20 mg/day) and either pindolol (5 mg t.i.d.) or placebo. Patients were evaluated with the Hamilton depression scale, the Montgomery-Asberg Depression Rating Scale, and Global Clinical Impression (CGI) on days 0 (baseline), 5, 10, 15, 21, 25, 31, 60, 120, and 180.
Intermediate analysis of the first month's results for the first 100 patients (pindolol, N=50; placebo, N=50) was performed. At day 10 there were more improved patients (defined as patients with a maximum score of 10 on the Hamilton depression scale) in the pindolol plus paroxetine group (N=24; 48%) than in the placebo plus paroxetine group (N=13; 26%). At day 5 there was no statistically significant difference, and at day 15 and thereafter, the differences between the two groups disappeared. Hamilton depression scale scores were significantly lower on days 5 and 10 for the pindolol plus paroxetine group (mean=15.7, SD=5.3, and mean=11.7, SD=6.4, respectively) than for the placebo plus paroxetine group (mean=19, SD=5.9, and mean=14.7, SD=6.8); this was also true for Montgomery-Asberg depression scale and CGI scores.
The addition of pindolol to paroxetine treatment significantly accelerates the onset of therapeutic response in patients suffering from major depression. Nevertheless, the mechanism (pharmacodynamic or pharmacokinetic) of this beneficial effect remains unclear.
本研究旨在探讨吲哚洛尔对加速帕罗西汀在重度抑郁症患者中起效的作用。
符合非精神病性障碍DSM-IV标准、既往无重度抑郁发作治疗史且17项汉密尔顿抑郁量表评分至少为18分的患者,在最初21天被随机分配接受帕罗西汀(20毫克/天)联合吲哚洛尔(5毫克,每日三次)或安慰剂治疗。在第0天(基线)、第5天、第10天、第15天、第21天、第25天、第31天、第60天、第120天和第180天,使用汉密尔顿抑郁量表、蒙哥马利-阿斯伯格抑郁量表和整体临床印象(CGI)对患者进行评估。
对前100例患者(吲哚洛尔组,N = 50;安慰剂组,N = 50)第一个月的结果进行中期分析。在第10天,吲哚洛尔加帕罗西汀组(N = 24;48%)中病情改善的患者(定义为汉密尔顿抑郁量表最高分为10分的患者)比安慰剂加帕罗西汀组(N = 13;26%)更多。在第5天没有统计学显著差异,在第15天及之后,两组之间的差异消失。吲哚洛尔加帕罗西汀组在第5天和第10天的汉密尔顿抑郁量表评分(分别为均值 = 15.7,标准差 = 5.3,以及均值 = 11.7,标准差 = 6.4)显著低于安慰剂加帕罗西汀组(均值 = 19,标准差 = 5.9,以及均值 = 14.7,标准差 = 6.8);蒙哥马利-阿斯伯格抑郁量表和CGI评分也是如此。
在帕罗西汀治疗中添加吲哚洛尔可显著加速重度抑郁症患者治疗反应的起效。然而,这种有益作用的机制(药效学或药代动力学)仍不清楚。